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25-Hydroxy vitamin DAbstract Background: Recurrent aphthous stomatitis (RAS) is characterized by recurrent,
painful, shallow, round or oval oral ulcers surrounded by inﬂammatory halos.
Aim of the work: To investigate the status of vitamin D in RAS patients and the relationship
between vitamin D levels and the severity of RAS.
Patients and methods: In this cross sectional study 46 patients with idiopathic minor RAS
(MIRAS), and 49 age and sex matched healthy controls were included. Patients with at least 3
minor aphthous oral ulcers in a year without any known cause for RAS were determined as
idiopathic minor recurrent aphthous stomatitis. The severity of RAS was assessed by the number
of oral aphthous ulcers in each attack and the frequency of attacks. 25-Hydroxy vitamin D
[25(OH) D] levels were measured by the Enzyme-Linked Immunosorbent Assay (ELISA) method
in patients and control groups.
Results: The mean 25(OH) D level in the MIRAS group was lower than the control group
(12.1 ± 7.7 ng/dl vs. 27.4 ± 9.7 ng/dl, p= 0.0001). Insufﬁciency and deﬁciency of 25(OH) D in
the recurrent aphthous stomatitis groups were more common than those in the control group
(Vitamin D sufﬁcient, Vitamin D insufﬁcient and Vitamin D deﬁcient (p< 0.0001 for all the
cases)). No correlation was found between the serum levels of 25(OH) D and the duration of
RAS, the number of oral aphthous ulcers in each attack, and the frequency of attacks (p< 0.05
for all the cases).
Conclusions: Our study suggests that deﬁciency of vitamin D may be a trigger factor for RAS.
 2014 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Rheumatic Diseases.1. Introduction
Recurrent aphthous stomatitis (RAS) is characterized by
recurrent, painful, shallow, round or oval oral ulcers sur-
rounded by inﬂammatory halos. RAS is the most frequent
ulcerative diseases of the oral mucosa [1] and may affect up
to 25% of population [2–5]. Three clinical forms of RAS have
134 A. Khabbazi et al.been described: minor RAS (MiRAS), major RAS (MaRAS),
and herpetiform ulcerations [6]. MiRAS is the most common
form, in which the ulcers are less than 1 cm in diameter and
heal without scar. Major ulcers are over 1 cm in diameter, take
longer to heal and often heal with scar. Herpetiform ulcers
manifest as recurrent crops of dozens of small ulcers through-
out the oral mucosa.
The pathogenesis of RAS is not clear, but immune dysreg-
ulation may play an important role [7–17]. Many studies have
disclosed the involvement of acquired immunity in the patho-
genesis of RAS. Hayrinen-Immonen et al. showed a dense inﬁl-
tration of lymphocytes and monocytes adjacent to the
damaged cells in oral aphthous lesions [18,19]. Initially,
CD4+ T cells are predominant but during the ulcerative stage
CD8+ become predominant. The local release of pro-inﬂam-
matory cytokines such as tumor necrosis factor (TNF), inter-
leukin-2 (IL-2) and interferon-c represents a dominant Th1
response in RAS [20]. Keratinocyte death is thought to be
mediated by the cytotoxic T-cells and the cytokines like TNF
produced by these leukocytes and other inﬂammatory cells
[21]. Like Behcet’s disease (BD), the role of the cd T-cells in
the pathogenesis of RAS has been introduced [22]. The alter-
ation of innate immune systems is also involved in the patho-
genesis of RAS. A recent study showed a higher expression of
Toll-like receptor 2 (TLR2) and a lower expression of TLR3
and TLR5 in the oral mucosa of patients with RAS [23]. BD
which is characterized by the attacks of RAS, genital ulcers,
skin lesions and uveitis share some common immunopatho-
genic mechanisms with RAS. However, it is not clear why
lesions in RAS are limited to the oral cavity, while BD is a
multisystem disease.
A growing body of evidence suggests that vitamin D has
immunomodulatory effects and plays an important role in
the pathogenesis of T-cell-mediated autoimmune diseases such
as rheumatoid arthritis (RA) [24–26] and systemic lupus ery-
thematosus (SLE) [27–32]. Recent studies also showed the role
of vitamin D deﬁciency in the pathogenesis of BD [33–36]. To
the best of our knowledge, no study has been performed about
the status of vitamin D in RAS.
The aim of the work: Given the likely importance of vitamin
D in the pathogenesis of RAS, the aim of this study was to
investigate the status of vitamin D in patients with RAS and
the relationship between vitamin D levels and the severity of
RAS.2. Patients and methods
In this cross sectional study 46 patients with idiopathic
MiRAS, and 49 age and sex matched healthy controls were
included. Patients with at least 3 minor aphthous oral ulcers
in a year without any known cause for RAS were determined
as idiopathic MiRAS. RAS was diagnosed by an expert physi-
cian according to the clinical characteristics of ulcers. The
study design was approved by the Ethics Committee of the
Tabriz University of Medical Sciences (TUOMS). Patients
with MiRAS and healthy controls after explaining the aims
of the study and obtaining written informed consents in accor-
dance with the Declaration of Helsinki were recruited to the
study. The study group was selected consecutively from the
outpatient clinic of connective tissue disease research center
between February 2013 and April 2013. Exclusion criteria werethe treatment with vitamin D supplements, steroids, colchicine,
disease modifying anti-rheumatic drugs (DMARDs), and anti-
convulsant drugs in the past 6 months; the use of anti-solar
creams; pregnancy; chronic renal failure, liver disease, thyroid
and parathyroid disorders; malnutrition; BD and ﬁbromyal-
gia. The severity of RAS was assessed by the number of oral
aphthous ulcers in each attack and the frequency of attacks.
The duration of RAS and frequency of attacks were docu-
mented on patient self-reporting.
Blood samples of the MiRAS group were obtained between
February 2013 and April 2013 and blood samples of the con-
trol group were obtained in April 2013. Separated serums were
collected and stored at 20 C until laboratory tests were
performed.
Vitamin D status was determined by the Enzyme-Linked
Immunosorbent Assay (ELISA) method. According to the
serum 25(OH) D level, each given participant was deﬁned as
Normal (30 < 25(OH) D < 100 ng/dl), Insufﬁcient (10 6
25(OH) D 6 30 ng/dl), or Deﬁcient (10 6 25(OH) D 6 30
ng/dl). Blinding was employed (test versus control samples)
prior to the ELISA analysis.
Statistical analysis: Statistical analyses were performed by
the SPSS software version 18.0 (SPSS Ins, Chicago, IL). The
Kolmogorov–Smirnov test was used to evaluate data distribu-
tion. Results are expressed as median (minimum–maximum
values), or mean ± SD and Mann–Whitney U test or indepen-
dent t test was used, as appropriate, to assess the signiﬁcance
of any differences between the two groups. All correlations
were evaluated using the Spearman test and the statistical sig-
niﬁcance was set at p< 0.05.
3. Results
Demographic and clinical characteristics of both study groups
are presented in Table 1. The mean 25(OH) D level in the RAS
group was lower than that in the control group (Fig. 1).
Patients and control group classiﬁcation according to Vitamin
D status is presented in Table 2. Insufﬁciency and deﬁciency of
25(OH) D in the RAS groups were more common than those
in the control group (Table 2). The levels of 25(OH) D were
correlated to the clinical characteristic of RAS. No correlation
was found between the serum levels of 25(OH) D and the dura-
tion of RAS (r= 0.079; p= 0.690), the number of oral aph-
thous ulcers in each attack (r= 0.024; p= 0.870), and the
frequency of attacks (r= 0.187; p= 0.225) in this group.
4. Discussion
Our study showed that 25(OH) D in the patients with MiRAS
is lower than that in the control group. However, there is no
relation between 25(OH) D levels and the clinical characteristic
of MiRAS. This is the ﬁrst study that compares 25(OH) D in
the patients with RAS and the normal population and that
investigates the correlation between vitamin D status and
RAS.
Many studies showed that vitamin D has an important reg-
ulatory role in the function of immune system [37–39]. It
affects many aspects of the innate and adaptive immune sys-
tem. Vitamin D decreases antigen-presenting activity of mac-
rophages to lymphocytes by down regulation of the MHC II
and costimulatory receptor expression [40]. It also inhibits
Table 1 Demographic data and characteristics of the minor recurrent aphthous ulcers.
Characteristics mean ± SD MiRAS Control p value
Age (years) 33.4 ± 9.8 34.1 ± 10.1 NS
Sex (Female/Male) 18/28 19/30 NS
Disease duration (years) 8.2 ± 7.5 – –
Frequency of attacks/month 1.2 ± 1 – –
Number of aphthous ulcers/attack 1.9 ± 1 – –
MiRAS, minor recurrent aphthous ulcer; NS, non-signiﬁcant.
Figure 1 Comparison of the 25(OH) D concentrations between
minor recurrent aphthous stomatitis (MiRAS) patients and the
control group (12.1 ± 7.7 ng/dl vs. 27.4 ± 9.7 ng/dl, p= 0.0001).
Table 2 Vitamin D status in the minor recurrent aphthous
ulcer patients and control.
Vitamin D status
n (%)
MiRAS
(n= 46)
Control
(n= 49)
p value
Normal level 2 (4.3) 17 (34.7) 0.0001
Insuﬃcient 27 (58.7) 29 (59.2) 0.0001
Deﬁcient 17 (37) 3 (6.1) 0.0001
According to the serum 25(OH) D level, each given participant was
deﬁned as: Normal (30 < 25(OH) D < 100 ng/dl), Insufﬁcient
(10 6 25(OH) D 6 30 ng/dl), or Deﬁcient (25(OH) D< 10 ng/dl).
MiRAS, minor recurrent aphthous ulcer.
Vitamin D levels in RAS patients 135the differentiation of monocytes into dendritic cells (DCs) and
the T-cell stimulatory activity of DCs [41–43]. Vitamin D
decreases IL-12 and increases IL-10 production [43,44]. The
result is the inhibition of Th1 and Th17 cell development
[44]. The immune modulatory effect of 1,25(OH)2 D3 through
down-regulation of the expressions of TLR2 and TLR4 was
demonstrated in human monocytes in vitro model. Do et al.
showed that 25(OH) D levels inversely correlated with the
expressions of TLR2 and TLR4 in patients with BD [33].Macrophages and activated lymphocytes express vitamin D
receptors (VDR) [45]. Stimulation of VDR on macrophages
activates them and increases the production of TNF and IL-
1, while stimulation of lymphocytes VDR inhibits T cell prolif-
eration and production of cytokines. Vitamin D deﬁciency has
been found to be associated with several immune mediated dis-
eases, including RA, SLE, BD and inﬂammatory bowel dis-
eases [46], insulin dependent diabetes mellitus [47], and
multiple sclerosis [48]. Epidemiological evidence also indicates
an association between the vitamin D deﬁciency and an
increased incidence of immune mediated diseases. Cutolo
et al. showed a relationship between circannual vitamin D
serum levels and disease activity in RA in northern and Wes-
tern Europe [49]. In another study, Hyppo¨nen et al. reported
that vitamin D supplementation reduces the risk of diabetes
mellitus type 1 [50].
The complex role of vitamin D in the regulation of immune
system function, deﬁciency of vitamin D in autoimmune disor-
ders, and epidemiological studies suggest that the deﬁciency of
vitamin D is an important environmental factor in the patho-
genesis of immune mediated disorders. The relationship
between the immune system dysregulation and the pathogene-
sis of RAS, and the results of our study may also prove the role
of vitamin D deﬁciency in the pathogenesis of RAS.
In conclusion, the results of the present study suggest that
deﬁciency of 25(OH) D may be a trigger factor for RAS.
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